Researchers continue to excited about the medication , a groundbreaking dual agonist showing promising data in early trials for body loss . It functions by impacting two pathways : GLP-1 and GIP, https://abelgfmj212686.blogdigy.com/this-new-possibility-for-body-management-65164968